HUGE

FSD Pharma Inc.

HUGE | News | $0.4589 -2.15% -1.21% 280K

(0.0% 1d) (-28.6% 1m) (-65.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 18,397,691
http://www.fsdpharma.com
Sec Filling | Patents | 23 employees

(CA) FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

skin autoimmunity endocannabinoid nervous system

add to watch list Paper trade email alert is off

Press-releases

FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
CELH | News | $72.0 -0.04% -0.06% 3.7M

Consumer Non-Durables

| 4.59% | O: 2.41% H: 1.96% C: -1.01%
pharma update

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -20.6% | O: -1.51% H: 5.48% C: -0.56%
pharma nasdaq

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Published: 2024-03-05 (Crawled : 14:00) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -41.2% | O: -13.48% H: 15.52% C: 12.05%
pharma positive sclerosis treatment research results lucid-21-302 study

FSD Pharma Inc. Announces Closing of Private Placement
Published: 2023-12-05 (Crawled : 14:30) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -51.94% | O: 0.0% H: 3.85% C: -2.88%
pharma

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
Published: 2023-11-27 (Crawled : 13:30) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -60.02% | O: 6.4% H: 3.76% C: -5.26%
pharma order

FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023
Published: 2023-11-15 (Crawled : 15:30) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -54.15% | O: -0.92% H: 8.33% C: 7.41%
pharma management meeting

FSD Pharma and Celly Nu Enter Into Arrangement Agreement
Published: 2023-10-05 (Crawled : 12:30) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -59.37% | O: -0.81% H: 3.28% C: -2.46%
pharma agreement

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington
Published: 2023-09-22 (Crawled : 10:00) - globenewswire.com
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -63.52% | O: -5.11% H: 4.62% C: -3.85%
media rapid

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
Published: 2023-09-18 (Crawled : 12:00) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries

| -66.68% | O: 5.33% H: 6.32% C: 1.27%
pharma report lucid-ms safe trial results

FSD Pharma Announces Analyst Coverage Initiated by Singular Research
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
HUGE | News | $0.4589 -2.15% -1.21% 280K

Process Industries